Fig. 1 · Structure

Documents & Downloads

FR901464

Cat. No. A12702 CAS 146478-72-0
FR901464 is a potent anticancer natural product that lowers the mRNA levels of oncogenes and tumor suppressor genes.

In Stock

Publications for FR901464

1 publication citing this product

  1. Hiroaki Ohara, .et al. , Mol Ther Nucleic Acids, 2023, Jul 17;33:404-412 PMID: 37547287

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

FR901464 modulates pre-mRNA splicing in FKTN models. It promoted pseudo-exon skipping, while higher concentrations also caused unwanted exon skipping in patient-derived myotubes, limiting interpretation as selective splicing correction. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 0.0013 μM Cytotoxicity against human A549 cells after 72 hrs by XTT colorimetric assay [PMID: 18788726]
A549 GI50 1 nM Antiproliferative activity against human A549 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay 10.1039/C0MD00179A
DU-145 GI50 1.05 nM Antiproliferative activity against human DU145 cells assessed as growth inhibition measured after 48 hrs by MTT assay [PMID: 23517093]
HCT-116 GI50 1 nM Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay 10.1039/C0MD00179A
HEK293 IC50 0.58 μM Inhibition of Pre-mRNA splicing in human HEK293 cells using p32-labeled CDC14-15 pre-mRNA by exonjunction complex (EJC) immunoprecipitation assay [PMID: 23517093]
MCF7 IC50 0.0018 μM Cytotoxicity against human MCF7 cells after 72 hrs by XTT colorimetric assay [PMID: 18788726]
MCF7 GI50 1 nM Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay 10.1039/C0MD00179A
MCF7 GI50 1.1 nM Cytotoxicity against human MCF7 cells incubated for 7 to 10 days by MTS assay [PMID: 33974423]
MDA-MB-231 GI50 2.1 nM Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition measured after 48 hrs by MTT assay [PMID: 23517093]
P388 GI50 1 nM Antiproliferative activity against mouse P388 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay 10.1039/C0MD00179A
SK-OV-3 GI50 1.06 nM Antiproliferative activity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by MTT assay [PMID: 23517093]

11 records · Scroll to view more

FR901464 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of FR901464 from 2 published references. In vitro models include cultured FCMD patient-derived myotubes carrying FKTN c.647+2084G>T.

FR901464 In Vitro Studies

FR901464 increased an FKTN splicing-reporter signal in HEK293 cells. Separately, it inhibited proliferation of cancer cells and human fibroblasts, showing that strong cellular activity did not establish tumor selectivity. [1,2]

FKTN pseudo-exon reporter response

Cell-based study · HEK293 cells carrying a mutant FKTN exon 5–6/intron 5 HiBiT reporter with c.647+2084G>T; wild-type reporter and DMSO controls [1]

FR901464 increased reporter output and promoted pseudo-exon skipping. The dose response peaked at 3 nM among the reported doses; the luminescence readout is not a binding-potency measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mutant reporter luminescence relative to DMSOfold change 45.1-fold at 3 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
1, 3 and 10 nM (Figure 1H); 10 μM for RT-PCR confirmation in Figure 1G
Exposure duration
24 h after compound addition
Method
HiBiT luminescence with RT-PCR confirmation
Vehicle
DMSO
Reported limits
Figure 1 caption states mean ± SD, n = 4; shared assay Methods states three biological replicates. This discrepancy remains unresolved; no replicate count or significance is assigned to the adopted fold value.
Methods and source locations

Compound reported in the paper: FR901464; Compound label in the paper: FR901464

Evidence applies to the named parent compound in the reported model; analytical stereochemical identity and current Adooq lot equivalence were not established.

Results 2.1–2.2; Figure 1A–H; Methods Compounds and HiBiT assay

Mutant reporter luminescence relative to DMSO: HiBiT assay; exact fold from Results, not estimated from bars — Results 2.2; Figure 1H

Pseudo-exon skipping and unwanted exon skipping in patient-derived myotubes

Cell-based study · Cultured FCMD patient-derived myotubes carrying FKTN c.647+2084G>T [1]

FR901464 promoted skipping of the aberrant pseudo-exon, but higher concentrations also altered other FKTN exons. Fainter transcript bands at 10 nM than at 3 nM limited interpretation as selective correction.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
FKTN pseudo-exon and other exon compositionqualitative RT-PCR outcome Pseudo-exon skipping; additional exon-skipped products across exons 5–10; fainter inclusion and skipped bands at 10 nM versus 3 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
1, 3 and 10 nM
Exposure duration
1 day compound exposure after 5 days of differentiation (diagrams in Figures 1I and 2A)
Method
RT-PCR across FKTN exons 5–6 and 5–10
Vehicle
DMSO
Reported limits
No FR901464 protein-rescue endpoint is shown in the adopted panels. Independent donor replication for these specific FR panels is not established by the three-patient description.
Methods and source locations

Compound reported in the paper: FR901464; Compound label in the paper: FR901464

Evidence applies to the named parent compound in the reported model; analytical stereochemical identity and current Adooq lot equivalence were not established.

Results 2.2–2.3; Figures 1I and 2A; Methods Compounds, Cell culture and RNA isolation/RT-PCR

FKTN pseudo-exon and other exon composition: DMSO-controlled RT-PCR; no exact band densitometry inferred — Results 2.2–2.3; Figures 1I and 2A

Cancer-cell and fibroblast proliferation inhibition

Cell-based study · Colorectal cancer panel, COLO829 melanoma, HCC38 breast cancer, CT26 murine colon tumor cells, and human fibroblasts [2]

FR901464 inhibited proliferation in cancer cells and human fibroblasts; the fibroblast response does not support tumor-selective cytotoxicity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
50% reduction in cellular proliferation versus untreated cellsIC50 DLD1: 0.71 ng/ml; HCT116: 0.31 ng/ml; human fibroblasts: 0.18 ng/ml; entire reported panel: 0.18–0.71 ng/ml[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.1–500 ng/ml tested
Exposure duration
Figure 1A IC50 exposure duration is not unambiguously assigned in the shared Methods
Method
Cell counting kit; IC50 defined relative to untreated-cell proliferation
Vehicle
DMSO
Reported limits
Shared Methods lists 1, 3, 6, 12 and 96 h for time-dependency experiments, without explicitly assigning Figure 1A IC50 duration. Experiments independently repeated at least three times; exact n and numerical SD for each adopted IC50 are not stated in the read text.
Methods and source locations

Compound reported in the paper: FR901464; Compound label in the paper: FR

Evidence applies to the named parent compound in the reported model; analytical stereochemical identity and current Adooq lot equivalence were not established.

Results Sensitivity of cancer cell lines; Figure 1A; Methods Drugs and chemicals and Drug treatment in cell culture

50% reduction in cellular proliferation versus untreated cells: Cell counting kit; values explicitly reported in Results — Results Sensitivity of cancer cell lines; Figure 1A; Methods Drug treatment in cell culture

FR901464 In Vivo Studies

FR901464 inhibited RKO xenograft growth at reported time points but did not significantly inhibit HCT116 xenograft growth. Treatment-associated deaths in both cohorts substantially limited the animal efficacy findings. [2]

Model-dependent xenograft response with severe toxicity

Animal study · Female BALB/cAJcl-nu/nu mice, purchased at 5 weeks; subcutaneous HCT116 or RKO xenografts [2]

RKO tumor growth was significantly inhibited at reported time points, while HCT116 tumor growth was not significantly inhibited. Deaths followed FR901464 administration in both treated cohorts.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor growth compared with controls without FRreported significance RKO: P = 0.038 at day 14, P = 0.04 at day 18, P = 0.0086 at day 22; HCT116: no significant effect[2]
Deaths after intraperitoneal FR administrationcount HCT116: 3/7 at 0.5 mg/kg; RKO: 4/9 at 0.75 mg/kg[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every fourth day
Treatment course
Six treatments planned; deaths occurred during treatment
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
HCT116 xenografts
0.5 mg/kg
HCT116 xenograft cohort without FR, n = 7; vehicle treatment not specifiedNo significant tumor-growth inhibition; 3 of 7 treated mice died.[2]
RKO xenografts
0.75 mg/kg
RKO xenograft cohort without FR, n = 6; vehicle treatment not specifiedSignificant tumor-growth inhibition at the reported time points; 4 of 9 treated mice died.[2]
HCT116 xenografts
Model: Female BALB/cAJcl-nu/nu mice; HCT116 subcutaneous xenografts; treated n = 7, control n = 7 (Figure 1)
Reported limits: Animal injection vehicle and blinding/randomization are not specified in the read Methods.
RKO xenografts
Model: Female BALB/cAJcl-nu/nu mice; RKO subcutaneous xenografts; treated n = 9, control n = 6 (Figure 1)
Reported limits: Animal injection vehicle and blinding/randomization are not specified in the read Methods.
Methods and source locations

Compound reported in the paper: FR901464; Compound label in the paper: FR

Evidence applies to the named parent compound in the reported model; analytical stereochemical identity and current Adooq lot equivalence were not established.

Results Effect of FR on tumor growth; Figure 1G–H; Methods Human tumor xenografts

Tumor growth compared with controls without FR: Caliper tumor volume a × b²; Student’s t-test; time points as reported in Results — Results Effect of FR on tumor growth; Figure 1G–H; Methods Human tumor xenografts and Statistical analysis

Deaths after intraperitoneal FR administration: Mortality reported in Results; denominators are treated cohorts — Results Effect of FR on tumor growth

HCT116 xenografts · Figure 1G; Results Effect of FR on tumor growth; Methods Human tumor xenografts

RKO xenografts · Figure 1H; Results Effect of FR on tumor growth; Methods Human tumor xenografts

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 146478-72-0
Formula C27H41NO8
Molecular Weight 507.61
SMILES
C[C@H]1CC([C@H](O[C@H]1C/C=C(\C)/C=C/[C@@H]2[C@H](C3(C[C@@](O2)(C)O)CO3)O)C)NC(=O)/C=C/[C@H](C)OC(=O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

FR901464 Research References

  1. [1] Ohara H, Hosokawa M, Awaya T, et al. Branchpoints as potential targets of exon-skipping therapies for genetic disorders. Molecular therapy. Nucleic acids (2023). PMID: 37547287 DOI: 10.1016/j.omtn.2023.07.011 Source material
  2. [2] Yamano T, Kubo S, Yano A, et al. Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy. Oncotarget (2019). PMID: 30719229 DOI: 10.18632/oncotarget.26564 Source material

Publications

1 publication citing this product

  1. Hiroaki Ohara, .et al. , Mol Ther Nucleic Acids, 2023, Jul 17;33:404-412 PMID: 37547287

Added to your cart

View Cart Checkout
Loading...